A solid patent strategy
NOVAiCOS’ innovation is protected by a solid patent strategy, ensuring exclusivity and competitiveness in the field of immunotherapy for bone metastases. NOVAiCOS holds two key patents, covering both cancer treatment and osteoporosis therapy.
Novel anti-tumor therapeutic agents
The active ingredient ICOS-Fc encapsulated in biocompatible nanoparticles has proven effective as an anti-tumor agent. This formulation inhibits tumor growth and metastatization by inhibiting the formation of new vessels and modulating the immune response against the tumor. The action of ICOS-Fc is independent of the type of tumor and of the nanoparticles in which it is encapsulated.
View on WIPO Patentscope
Technical features
The patent describes the use of ICOS-Fc encapsulated in biodegradable and biocompatible nanoparticles in the treatment of neoplastic growth. In the transplantable B16 melanoma tumor model, ICOS-Fc encapsulated in β-cyclodextrin nanosponges shows a powerful antitumor activity by inhibiting primary tumor growth, tumor metastatization, tumor neoangiogenesis and tumor-mediated immunosuppression. The effect does not depend on the type of nanoparticles and the type of tumor, since a similar antitumor effect was detected using human ICOS-Fc loaded in poly(lactic-co-glycolic acid) (PLGA) nanoparticles in the same melanoma model or in a xenogenic model of glioblastoma. Taken together, these results indicate that ICOS-Fc has the potential to become a new tool for cancer therapies thanks to its multi-pronged anti-tumor activity, targeting essential stages of tumor growth.
Possible applications
- Inhibition of tumor growth and neo-angiogenesis
- Inhibition of tumor metastatization
- Bone metastasis
- Oncology field
Advantages
- Absence of cytotoxicity at the tested concentrations
- High tolerability and good stability in mice in vivo
- Ability to reduce neoplastic growth in several tumor models in mice
- Multi-level anti-tumor activity effective on tumor cells, tumor microenvironment and anti-tumor immune response
Ligands of the B7h receptor for the treatment of osteopenia and osteoporosis
ICOS-Fc inhibits osteoclast osteolytic activity in vitro and osteoporosis in vivo.
View on WIPO Patentscope